Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry

BACKGROUND: Vaccination programs have been launched worldwide to halt the spread of COVID-19. However, the identification of existing, safe compounds with combined treatment and prophylactic properties would be beneficial to individuals who are waiting to be vaccinated, particularly in less economic...

Descripción completa

Detalles Bibliográficos
Autores principales: Duarte, Rodrigo R. R., Copertino, Dennis C., Iñiguez, Luis P., Marston, Jez L., Bram, Yaron, Han, Yuling, Schwartz, Robert E., Chen, Shuibing, Nixon, Douglas F., Powell, Timothy R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426591/
https://www.ncbi.nlm.nih.gov/pubmed/34503440
http://dx.doi.org/10.1186/s10020-021-00356-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426591/
https://www.ncbi.nlm.nih.gov/pubmed/34503440
http://dx.doi.org/10.1186/s10020-021-00356-6

Ejemplares similares